Chronic Hand Eczema

Irritants, cleaning products, and mites tracked with SHE in 56,978 Dutch adults, although the exposure tool was built for occupational asthma.

Chronic hand eczema affects roughly 5% of adults each year, exacts most of its toll at work, and is not simply atopic dermatitis of the hands.

Although topical delgocitinib matched injectable dupilumab for CHE, real-world adherence could determine whether that holds outside clinical trials.

A retrospective study of 76 patients at a Spanish allergy clinic found occupational exposure suspected in more than half of chronic hand eczema cases, with patch testing tying most sensitizations to preservatives, nickel, and rubber accelerants.

In the DELTA TEEN trial, 64% of adolescents with moderate to severe chronic hand eczema achieved clear or almost clear skin with delgocitinib cream versus 29% on vehicle, with mostly mild adverse events and no safety signals.

A budget impact model projects that covering delgocitinib cream for moderate to severe chronic hand eczema could save a hypothetical US health plan $87.8 million over 3 years, driven mostly by lower drug costs.

New topicals, orals, and biologics are expanding chronic hand eczema treatment, but phenotype-specific data gaps remain.

Topical delgocitinib in chronic hand eczema improves clearance and itch fast, with placebo-like safety.

Structured CHE diagnosis improves outcomes: a multicenter CRF clarifies causes for most patients with chronic hand eczema, addressing diagnosis challenges and guiding targeted care.

Canadian dermatologists propose treat-to-target benchmarks for chronic hand eczema, pairing IGA-CHE and itch scores to guide therapy and follow-up.

Covering delgocitinib for chronic hand eczema could save a 1M-member plan $88M over 3 years, driven by lower drug costs than off-label therapies.

DELTA 2 data show topical delgocitinib for chronic hand eczema delivers minimal systemic absorption even under maximal-use conditions.

New US chronic hand eczema guidance closes diagnostic gaps and spotlights emerging therapies like delgocitinib to cut itch, pain, and work disruption.

Chronic hand eczema care is marked by high costs, fragmented treatment, and a clinical overreliance on steroids.

Delgocitinib led to notable improvement by week 4, which may have helped improve longer-term treatment adherence.

DELTA 3 trial extension data show sustained improvements in disease-specific, dermatology-specific, and overall quality-of-life measures.

CHECK-US data show chronic hand eczema is driven by multiple triggers and linked to moderate disease severity and significant quality-of-life burden.